The antitumor activity of the antineoplastic agent, tiazofurin (2-,jD-ribofuranosylthiazole-4-carboxamide), has previously been shown to require intracellular anabolism of the drug to a nicotinamide adenine dinucleotide (NAD) analog (2-f-Dribofuranosylthiazole-4-carboxamide adenine dinucleotide or "tiazofurin adenine dinucleotide"), which then acts as a potent inhibitor of the target enzyme inosine monophosphate (IMP) dehydrogenase. Inhibition of the latter enzyme in turn brings about a profound depletion of intracellular guanosine nucleotides essential for tumor cell growth and replication. In the present study, the cytotoxicity and metabolism of tiazofurin have been examined in six human lung cancer cell lines. At the pharmacologically attainable drug concentration of 100 AM, colony survival was <1.5% in three cell lines ("sensitive"), while survival in the remaining three was >50% ("resistant"). The metabolism of tritiated tiazofurin was examined at concentrations ranging from 0.5 to 100 AM following both brief (6 h) and protracted (14 d) exposures. The sensitive lines accumulated concentrations of tiazofurin adenine dinucleotide that were approximately 10 times those achieved by the resistant lines at both time points. We also observed tendencies for the sensitive cell lines to exhibit: (a) higher specific activities of NAD pyrophosphorylase, the enzyme required for the synthesis of tiazofurin adenine dinucleotide, (b) significantly lower levels of a phosphodiesterase which degrades the latter dinucleotide, (c) greater inhibition of the target enzyme IMP dehydrogenase, and (d) greater depressions of guanosine nucleotide pools after drug treatment. By contrast, the basal levels of IMP dehydrogenase and purine nucleotides in these six lines did not correlate in any obvious way with their responsiveness or resistance. The accumulation and monophosphorylation of parent drug were also not prognostic variables. These studies thus suggest that the extent of accumulation of tiazofurin adenine dinucleotide, as regulated by its synthetic and degradative enzyme activities, is the single most predictive determinant of
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Introduction
The C-nucleoside tiazofurin, (2-fl-D-ribofuranosylthiazole-4-carboxamide, Fig. 1 ), an analogue of the potent antiviral agent ribavirin (1) , has demonstrated significant antitumor activity against the L1210 and P388 murine leukemias and is curative of the Lewis lung carcinoma (2) . In vitro studies with four human malignant lymphoid cell lines established that the 50% inhibitory concentrations of tiazofurin were 30, 27, 7, and 6 1AM, which are values between 3 and 15 times higher than the 50% inhibitory concentration of the drug for P388 lymphocytes in culture (3, 4) . In metabolic studies, tiazofurin has been shown to depress guanosine nucleotide biosynthesis through its inhibition of inosine monophosphate dehydrogenase (IMPD)! (Fig. 2) (4, 5) . This inhibition in turn has been attributed to the formation of an analogue of nicotinamide adenine dinucleotide (NAD), tiazofurin adenine dinucleotide (TAD), in which the thiazole ring of tiazofurin has replaced nicotinamide (6, 7) (Fig. 1 ). In vitro, this "fraudulent" dinucleotide inhibits partially purified preparations of IMPD with an inhibition constant (K*) of 0.2 MM. Levels of TAD at least one order of magnitude greater than this have been shown to be formed in vivo (7) . Inasmuch as tiazofurin is presently being evaluated in phase I-II, clinical trials in patients with cancer, including lung cancer, we have evaluated the in vitro cytotoxicity of the drug in six human lung cancer cell lines using a soft agarose clonogenic assay. In addition, the metabolism of the drug was examined. The results of these experiments suggest that, in human lung cancer cells, the extent of accumulation of TAD, the proposed active metabolite of tiazofurin, may be the most important predictor of sensitivity of these cells to the drug. (300 U/mg) and hog liver NAD pyrophosphorylase were the product of Boehringer Mannheim Corp., Indianapolis, IN. All other reagents used were of the highest purity available. Methods for the growth and characterization of the cell lines used in this study have been described previously (8-1 1) . Briefly, all cultures were established from patients with a histologically confirmed diagnosis of lung cancer and maintained in RPMI 1640 culture medium (Gibco Laboratories, Grand Island, NY) supplemented with 10% heat-inactivated fetal bovine serum. The cell lines evaluated included four derived from patients with small cell lung cancer (SCLC) (H82, H 146, H249, and N417), and two derived from patients with adenocarcinoma of the lung (H23 and H125). The in vitro doubling times of the lines were: H23 (38 h); H82 (33 h); H125 (39 h); H146 (54 h); H249 (36 h); and N417 (24 h ). The SCLC cell lines could be divided into two groups: classic SCLC cell lines (SCLC-C, H 146, and H249) and variant SCLC cell lines (SCLC-V, H82, and N417). The SCLC-C cell lines have typical SCLC morphology, grow as floating cell aggregates, and express elevated levels of L-dopa decarboxylase (E.C. 41.1.28), neuron specific enolase, creatine kinase BB, and the peptide hormone bombesin (8, 10, 11) . In contrast, the SCLC-V cell lines, which also grow as floating aggregates of cells, do not express typical SCLC amine precursor uptake and decarboxylation markers including L-dopa decarboxylase or peptide hormones (8, 10, 11) . However, in contrast to non-SCLC cells, the SCLC-V exhibit the SCLC properties of elevated levels of creatine kinase BB. At In vitro test ofcytotoxicity
Sensitivity of the six cell lines to tiazofurin was tested using a soft agarose clonogenic assay as previously described (12) (13) (14) (15) To determine the effect of short-term exposure, cells were first incubated with the drug for 6 h in liquid culture and then resuspended in tiazofurin-free culture medium fortified with 0.3% agarose. Subsequent treatment of the cultures was then identical with that described above, with colonies being scored at 14 d.
Determination of tiazofurin metabolites
Short-term incubations. Cell lines were treated with tiazofurin at three different concentrations of the drug (1, 10, and 100 AM, along with tritiated drug, 50 ;XCi/flask). After 6 h of exposure to the drug, cells were centrifuged at 1000 g in a Sorvall centrifuge (Ivan Sorvall Inc., Newtown, CT) for 3 min. The cell pellet was washed with cold Hanks' balanced salt solution, pelleted through Versilube oil (General Electric Co., Waterford, NY), and extracted with 500 Ml of 10% trichloroacetic acid (TCA). The protein-free supernatant was neutralized with 0.5 M trioctylamine in freon (16) . Neutralized samples were loaded onto a Partisil 10-SAX column (Waters Associates, Milford, MA) preequilibrated with 0.03 M ammonium phosphate buffer, pH 3.5. Tiazofurin and its metabolites were eluted using a linear gradient of 0.03 M ammonium phosphate, pH 3.5, to 0.6 M ammonium phosphate, pH 4.6 (6) ; under these conditions, tiazofurin, tiazofurin-5'-monophosphate (TRMP) and TAD eluted at 3, 7, and 18 min, respectively. Metabolite concentrations were quantitated by measuring the radioactivity eluting in these peaks.
Long-term incubation. Long-term incubations were carried out essentially as described above except that tritiated tiazofurin was present for a full 14-d incubation at a concentration of 0. 5 considerable heterogeneity in the dose-response of these lines was observed: thus, the 50% inhibitory concentrations ranged from -10 to '-500 WM. At a concentration of l0-4 M, the six cell lines could be divided into two groups based on their relative sensitivity to tiazofurin. Three cell lines, N417, H82, and H23, had colony survival of <1.5% (Fig. 3 B) and were considered to be "sensitive" to tiazofurin, while the remaining three cell lines, at the same drug concentration, had colony survival ranging from 50 to 75% and were labeled "resistant."
Repetition of these studies on the same lines 12 mo later yielded virtually identical results.
Short-term accumulation and metabolism of tiazofurin by human lung cancer cell lines in culture. 6 h after treatment with tiazofurin (1, 10, and 100 jIM, 50 jICi/flask), drug metabolites were analyzed by HPLC (Table I ). The six lines accumulated parent drug to variable degrees, but the intracellular drug concentrations achieved did not correlate in any Enzymology of TAD synthesis. Since the accumulation of TAD was found to be notably greater in the sensitive as compared with the resistant lines, a logical next step was to examine the enzymology of its synthesis. This anabolite is formed from tiazofurin in a two-step process (Fig. 2) . The first enzymatic step is the conversion of tiazofurin to its 5'-monophosphate, TRMP. Since the accumulation of TRMP was found to be roughly similar in all cell lines studied, the possibility that the phosphorylation step is impaired in the resistant lines was ruled out. The critical step resulting in TAD accumulation is believed to be the conversion of TRMP to TAD. The enzyme NAD-pyrophosphorylase has been identified as catalyzing this reaction (6) , with TRMP and ATP as substrates. Although overlaps and variability were observed for this activity in the two groups (Table II) , the sensitive lines exhibited a mean specific activity of NAD-pyrophosphorylase which was 212% of the-activity in the resistant lines.
Enzymology of TAD breakdown. Using labeled TAD as substrate, it was possible to examine the capability of the six human lung tumor cell lines to catalyze the phosphodiesteratic degradation to TAD to its constituent nucleotides, TRMP and AMP (Table II) . This activity, which was largely soluble, was significantly lower in the sensitive lines (43.3 nmol/h/mg protein) than in their resistant counterparts (159.9 nmol/h/mg protein).
Influence of tiazofurin treatment on IMPD activity in cultured human cell lines. It has been shown previously that TAD is a potent inhibitor of IMPD (6, 7) . IMPD activity was measured in the sensitive and resistant lines treated with tiazofurin (100 MM, 6 h) or saline. Some variability was observed in the basal activity of this enzyme in the six cell Influence of tiazofurin treatment on nucleotide concentrations. The levels of endogenous purine and pyrimidine nucleotides are shown in Table III . The basal concentrations of these nucleotides were found to be variable among the six lines, with no correlation to their sensitivity or resistance. Tiazofurin treatment (100 ,uM) for 6 h altered the nucleotide pools in these cells, as documented in Table IV . Thus, guanosine nucleotide concentrations underwent a marked reduction in all three sensitive lines, and, perplexingly, in one of the resistant cell lines; an increase in the IMP pool size accompanied this effect. Pyrimidine nucleotide pools were found to increase in two of the three sensitive, and one of the three resistant strains.
Discussion
The use of soft agarose clonogenic assays for predicting in vivo responses to chemotherapeutic agents and evaluating new agents has recently achieved clinical application (14, 15, (18) (19) (20) (21) . However, although moderate success is being reported with the use of this approach, the many problems with the cloning of fresh specimens, including adequate colony growth in only 20-50% of all patient specimens, suggest that the widespread use of this assay will be limited until significant improvements are made in both tumor processing and growth conditions (9, 13, 22, 23) . (27) . While some studies suggest that, with continuous culture, the chemosensitivity patterns of cell lines may change (24), we have recently shown that both small cell and nonsmall cell lung cancer cells retain in vitro sensitivity to a range of compounds with known clinical activity in the treatment of these tumors (28, 29) . In addition, in vitro radiation biological studies have correlated well with the clinical radiation responses observed in small cell and nonsmall cell lung cancer patients (28) . Thus, the data suggest that serially propagated cultures of human lung cancer cells may have application both for the screening of drugs for phase I/II clinical trials, and, possibly more importantly, for determining mechanisms of resistance to cytotoxic agents.
The present experiments were carried out with six such lines exposed in vitro to the novel oncolytic C-nucleoside, tiazofurin. In three of the lines, clonogenicity was virtually abolished by continuous exposure to 100 ,M tiazofurin, whereas the three remaining strains proliferated fairly normally at this concentration of drug. The former three cell lines were considered to be sensitive to tiazofurin and the latter three resistant. Although this cut-off is somewhat arbitrary, it is rendered reasonable by pharmacokinetic studies in rodents, rabbits, and dogs, which suggest that blood levels > 100 ,uM are unlikely to be sustained after doses of the drug in the therapeutic range (30) By contrast, the results of enzymatic measurements of the rate of TAD breakdown, (by 'TAD-phosphodiesterase'), correlated positively with the state of resistance (Table II) .
Other parameters whose correlation to sensitivity or resistance was imperfect included: basal IMPD activity; percentage inhibition of IMPD; percentage elevation of IMP following exposure to tiazofurin; and percentage depression of guanosine nucleotides produced by the drug. The failure of this last parameter to correlate with responsiveness or resistance in an absolute way is especially perplexing in view of the proposed mechanism of action of tiazofurin. However, as Table IV documents, in two of the three resistant strains, H146 and H125, only minor depressions in guanosine nucleotide pools ensued after incubation with tiazofurin. By contrast, in H249, a 71% decrease in guanosine nucleotides was produced by the drug and it was this value which skewed the mean.
When taken together, the results of the present studies establish that certain cultured lung tumor cells respond to pharmacologically attainable levels oftiazofurin, whereas certain other lines do not. It is noteworthy that the two SLCL-V cell lines, H82 and N417, were both sensitive to tiazofurin, while the classic SCLC cell lines, H146 and H249, were resistant to the drug. We have previously shown that these SCLC-V cell lines have a more "malignant" behavior in vitro including higher cloning efficiency and increased tumorigenicity in nude mice than their pure SCLC counterparts (8) (9) (10) (11) . In addition, SCLC-V cell lines have increased resistance to X-rays in vitro (28, 29) , and have a high degree of amplification (20-75-fold) of c-myc DNA and greatly increased levels of the c-myc RNA (31) . Clinical correlates of the SCLC-V have also been observed (32) . Patients with the SCLC-V phenotype have a poorer response to chemotherapy, and a shorter survival time than patients with pure SCLC. Whether the increased in vitro sensitivity of the SCLC-V to tiazofurin will translate into clinical efficacy of the drug remains to be seen.
Differential sensitivity with respect to histologic type was not observed for adenocarcinoma cell lines (H23, 'S', and H125, 'R'). It is also of interest to note that cell lines H82 and H23, which were found in previous studies to be resistant to a wide range of oncolytic agents (29) , showed sensitivity to tiazofurin treatment in vitro. These data suggest that tiazofurin might be useful in treating lung cancer resistant to standard chemotherapeutic agents. The stability of these cell lines in both their sensitivity to and their metabolic handling of tiazofurin over a 12 mo interval (Table II) reinforces the above contention.
Correlating the cytotoxicity oftiazofurin with its metabolism in vitro, it can be concluded that the measurement of the extent of accumulation of the proximate antimetabolite, TAD, by these six lines was of real predictive value in assessing sensitivity or resistance to the drug. The applicability of this observation to sensitivity or resistance in vivo will be examined in the course of ongoing clinical studies.
